Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for untreated advanced hepatocellular carcinoma.
Status In progress
Process STA 2018
ID number 1248

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 May 2018 - 07 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance